Groupama Asset Managment Sells 5,332 Shares of Becton, Dickinson and Company $BDX

Key Points

• Groupama Asset Managment has reduced its stake in Becton, Dickinson and Company by 49.6%, now holding 5,414 shares worth approximately $1.23 million.
• Insider sales included Director Claire Fraser, who sold 863 shares worth about $165,955, and EVP Michael David Garrison, who sold 1,185 shares valued at $213,644.
• Becton, Dickinson reported earnings of $3.68 per share for the last quarter, exceeding estimates, and set a fiscal year 2025 guidance of $14.30-14.45 EPS.

Groupama Asset Managment lessened its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 49.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,414 shares of the medical instruments supplier's stock after selling 5,332 shares during the period. Groupama Asset Managment's holdings in Becton, Dickinson and Company were worth $1,232,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC bought a new stake in Becton, Dickinson and Company in the 1st quarter worth $27,000. REAP Financial Group LLC grew its holdings in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 55 shares during the last quarter. Alpine Bank Wealth Management bought a new stake in Becton, Dickinson and Company in the 1st quarter worth $29,000. Cornerstone Planning Group LLC grew its holdings in Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 99 shares during the last quarter. Finally, Nexus Investment Management ULC bought a new stake in Becton, Dickinson and Company in the 1st quarter worth $34,000. Institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Up 1.5%

NYSE BDX traded up $2.8730 during trading hours on Friday, reaching $199.5030. 1,619,788 shares of the company's stock traded hands, compared to its average volume of 2,720,196. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The firm has a market cap of $57.18 billion, a PE ratio of 35.88, a PEG ratio of 1.49 and a beta of 0.20. The firm has a 50-day simple moving average of $180.65 and a 200 day simple moving average of $195.26. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.51 billion during the quarter, compared to analysts' expectations of $5.50 billion. During the same period last year, the company posted $3.50 EPS. Becton, Dickinson and Company's revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Analyst Ratings Changes

BDX has been the topic of a number of research reports. Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and cut their target price for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Raymond James Financial lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Piper Sandler reaffirmed a "neutral" rating and set a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 target price on the stock. in a research note on Friday, May 2nd. Finally, Bank of America lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price on the stock. in a research note on Thursday, May 1st. Four research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $211.44.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Shan sold 1,166 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president directly owned 4,575 shares of the company's stock, valued at $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,214 shares of company stock valued at $579,206. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.